×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Cervical Cancer

Alexandra Guadagno
The FDA has approved Zirabev, a biosimilar to Avastin, for the treatment of five types of cancer: colorectal cancer; non-small cell lung cancer; glioblastoma; metastatic renal cell carcinoma; and persistent, recurrent or metastatic cervical cancer.
Stephanie Fraser, M.S.W.
A essay nominating Kimberly Spina, B.S.N., RN for CURE®’s Extraordinary Healer® Award, written by Stephanie Fraser, M.S.W., of The University of Vermont Cancer Center.
Jessica Skarzynski
Here are the top 5 CURE stories for January 2019.
Katie Kosko
Nearly 90 percent of women experienced sexual dysfunction; however, providers were not openly communicating about this side effect, according to survey results.
Brielle Benyon
In conjunction with Cervical Cancer Awareness Month, recognized in the month of January, here are some fast facts about the disease.
Brielle Urciuoli
The Food and Drug Administration (FDA) approved an expanded age indication for GARDASIL 9 (Human Papillomavirus 9-valent Vaccine, Recombinant), according to Merck, the manufacturer of the HPV vaccine.
 
Jessica Skarzynski
Non-pharmacologic integrative medicine approaches such as aromatherapy and reflexology can dramatically reduce the pain and anxiety associated with cervical radiation therapy, according to a clinical study currently underway at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James).
 
Kristie L. Kahl
The application is seeking approval for GARDASIL 9 to be used in women and men aged 27 to 45 years for the prevention of certain cancers and diseases caused by the nine human papillomavirus (HPV) types covered by the vaccine.
Brielle Urciuoli
The Food and Drug Administration approved Keytruda (pembrolizumab) for the treatment of certain patients with cervical cancer.
Jason Harris
Keytruda (pembrolizumab) was granted a priority review by the Food and Drug Administration (FDA) for the treatment of patients with advanced cervical cancer with disease progression or after chemotherapy.
 
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

Patient Caregiver Advocate Other